Celcuity to Participate in the Cowen 42nd Annual Health Care Conference
03/02/2022 - 07:30 AM
MINNEAPOLIS, MN / ACCESSWIRE / March 2, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating patients with cancer, today announced its participation in the virtual Cowen 42nd Annual Health Care Conference to be held March 7-9, 2022. Brian Sullivan, Chairman, Chief Executive Officer, and Co-founder of Celcuity, is scheduled to participate in the "Breast Cancer" corporate panel session at 2:10 p.m. ET on Wednesday, March 9, 2022.
A live webcast of the panel session will be available using this weblink: https://wsw.com/webcast/cowen108/panel23/2324601 . Alternatively, the live webcast will be accessible from the Investors section of the company's website at https://celcuity.com/investors/events-webcasts/ with a replay available shortly after the live event.
About Celcuity
Celcuity is a clinical-stage biotechnology company seeking to extend the lives of cancer patients by pursuing an integrated therapeutic and companion diagnostic strategy. The company's therapeutic efforts are focused on in-licensing and developing molecularly targeted therapies that address the same cancer driver its companion diagnostics can identify. Its CELsignia companion diagnostic platform is uniquely able to analyze live patient tumor cells to identify new groups of cancer patients likely to benefit from already approved targeted therapies. Celcuity is headquartered in Minneapolis. Further information about Celcuity can be found at www.celcuity.com .
Contacts:
Celcuity Inc.bsullivan@celcuity.com vhahne@celcuity.com
ICR Westwickerobert.uhl@westwicke.com
SOURCE: Celcuity Inc.
https://www.accesswire.com/690965/Celcuity-to-Participate-in-the-Cowen-42nd-Annual-Health-Care-Conference
CELC Rankings
#2062 Ranked by Stock Gains
CELC Stock Data
Industry
Medical Laboratories
Sector
Health Care and Social Assistance
Tags
Commercial Services, Miscellaneous Commercial Services, Health Care and Social Assistance, Medical Laboratories
About CELC
celcuity is a biotech company developing state-of-the-art cell-based assays using our proprietary functional cellular analysis platform. we directly assess the functionality of the disease-related signaling pathways of a patient's diseased cells ex vivo to determine whether a drug therapy has the intended effect on those cells. the patient specific cellular data we provide offers clinicians and pharmaceutical companies unique insight into a patient's response to a drug therapy, and it will change the paradigm of personalized medicine.
